Leland Gershell
Stock Analyst at Oppenheimer
(4.27)
# 1,395
Out of 4,534 analysts
731
Total ratings
40.6%
Success rate
7.8%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Rated: Buy | $40 → $50 | $41.12 | +21.60% | 47 | Jul 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | n/a | $83.87 | - | 20 | Jul 7, 2026 | |
| EQ Equillium | Reiterated: Buy | $7 | $2.47 | +183.40% | 3 | Jun 30, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,014 | $846.19 | +19.83% | 17 | Jun 24, 2026 | |
| OKUR OnKure Therapeutics | Maintained: Buy | $30 | $4.12 | +628.16% | 2 | Jun 24, 2026 | |
| FULC Fulcrum Therapeutics | Rated: Hold | n/a | $3.62 | - | 2 | Jun 22, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | n/a | $1.87 | - | 8 | Jun 22, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $54 | $19.50 | +176.92% | 23 | Jun 18, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $262 | $251.76 | +4.07% | 37 | Jun 15, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $14 | $3.51 | +298.86% | 7 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $283 → $230 | $44.50 | +416.85% | 4 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $4.07 | +587.96% | 21 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.7045 | +1,319.45% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $12.22 | +47.30% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $16.77 | +43.11% | 17 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.33 | +651.88% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.56 | - | 34 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $4.55 | +339.56% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $162 → $277 | $293.99 | -5.78% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $21 | $5.53 | +279.75% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $2.30 | +986.96% | 44 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $30.95 | - | 7 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $39.92 | +35.27% | 8 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2,000 | $18.82 | +10,526.99% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $8.60 | +109.30% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $104.60 | - | 6 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $59.11 | +65.79% | 38 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.34 | +70.94% | 3 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $18.21 | +92.20% | 28 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $32.07 | +149.45% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $490 | $272.67 | +79.70% | 42 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.31 | n/a | 20 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $31.00 | n/a | 10 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $106 | $79.11 | n/a | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.7173 | n/a | 19 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.68 | n/a | 17 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $1.18 | n/a | 19 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.43 | n/a | 16 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.73 | n/a | 6 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $0.135 | n/a | 11 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $200 | $0.0001 | n/a | 11 | Mar 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.89 | n/a | 16 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $0.01316 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $0.26 | n/a | 11 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $1.15 | n/a | 16 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $1.50 | n/a | 7 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0111 | n/a | 4 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.60 | n/a | 13 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.75 | n/a | 22 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.38 | n/a | 9 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0075 | n/a | 15 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.03 | n/a | 3 | May 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | n/a | 9 | May 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.20 | n/a | 9 | Apr 3, 2019 |
UroGen Pharma
Jul 16, 2026
Rated: Buy
Price Target: $40 → $50
Current: $41.12
Upside: +21.60%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $83.87
Upside: -
Equillium
Jun 30, 2026
Reiterated: Buy
Price Target: $7
Current: $2.47
Upside: +183.40%
argenx SE
Jun 24, 2026
Reiterated: Buy
Price Target: $1,014
Current: $846.19
Upside: +19.83%
OnKure Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: $30
Current: $4.12
Upside: +628.16%
Fulcrum Therapeutics
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $3.62
Upside: -
enGene Therapeutics
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $1.87
Upside: -
Capricor Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $54
Current: $19.50
Upside: +176.92%
Ascendis Pharma
Jun 15, 2026
Reiterated: Buy
Price Target: $262
Current: $251.76
Upside: +4.07%
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $14
Current: $3.51
Upside: +298.86%
May 27, 2026
Reiterated: Buy
Price Target: $283 → $230
Current: $44.50
Upside: +416.85%
May 20, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $4.07
Upside: +587.96%
May 15, 2026
Reiterated: Buy
Price Target: $10
Current: $0.7045
Upside: +1,319.45%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $12.22
Upside: +47.30%
May 8, 2026
Reiterated: Buy
Price Target: $24
Current: $16.77
Upside: +43.11%
May 6, 2026
Reiterated: Buy
Price Target: $10
Current: $1.33
Upside: +651.88%
Apr 13, 2026
Rated: Hold
Price Target: n/a
Current: $18.56
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: $20
Current: $4.55
Upside: +339.56%
Feb 27, 2026
Maintained: Buy
Price Target: $162 → $277
Current: $293.99
Upside: -5.78%
Feb 27, 2026
Maintained: Buy
Price Target: $35 → $21
Current: $5.53
Upside: +279.75%
Feb 12, 2026
Reiterated: Buy
Price Target: $25
Current: $2.30
Upside: +986.96%
Feb 10, 2026
Rated: Hold
Price Target: n/a
Current: $30.95
Upside: -
Feb 9, 2026
Maintained: Buy
Price Target: $54
Current: $39.92
Upside: +35.27%
Nov 14, 2025
Maintained: Buy
Price Target: $2,000
Current: $18.82
Upside: +10,526.99%
Nov 7, 2025
Maintained: Buy
Price Target: $18
Current: $8.60
Upside: +109.30%
Nov 4, 2025
Downgraded: Hold
Price Target: n/a
Current: $104.60
Upside: -
Oct 28, 2025
Reiterated: Buy
Price Target: $98
Current: $59.11
Upside: +65.79%
Oct 14, 2025
Reiterated: Buy
Price Target: $4
Current: $2.34
Upside: +70.94%
Sep 29, 2025
Reiterated: Buy
Price Target: $35
Current: $18.21
Upside: +92.20%
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $80
Current: $32.07
Upside: +149.45%
Aug 4, 2025
Upgraded: Buy
Price Target: $490
Current: $272.67
Upside: +79.70%
Sep 16, 2024
Maintained: Buy
Price Target: $25
Current: $1.31
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $31.00
Upside: n/a
May 14, 2024
Maintained: Buy
Price Target: $106
Current: $79.11
Upside: n/a
Mar 28, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $0.7173
Upside: n/a
Dec 18, 2023
Maintained: Buy
Price Target: n/a
Current: $3.68
Upside: n/a
Nov 13, 2023
Maintained: Buy
Price Target: $11
Current: $1.18
Upside: n/a
Jul 10, 2023
Maintained: Buy
Price Target: n/a
Current: $2.43
Upside: n/a
Oct 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $5.73
Upside: n/a
May 26, 2022
Maintained: Buy
Price Target: $60
Current: $0.135
Upside: n/a
Mar 21, 2022
Maintained: Buy
Price Target: $70 → $200
Current: $0.0001
Upside: n/a
Nov 16, 2021
Reiterated: Hold
Price Target: n/a
Current: $8.89
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $0.01316
Upside: n/a
Jun 2, 2021
Rated: Buy
Price Target: $12
Current: $0.26
Upside: n/a
May 18, 2021
Rated: Buy
Price Target: $7
Current: $1.15
Upside: n/a
May 7, 2021
Initiated Coverage: Buy
Price Target: $42
Current: $1.50
Upside: n/a
May 6, 2021
Maintained: Hold
Price Target: n/a
Current: $0.0111
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $13.60
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $8.75
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $1.38
Upside: n/a
Sep 11, 2020
Rated: Hold
Price Target: n/a
Current: $0.0075
Upside: n/a
May 10, 2019
Reiterated: Buy
Price Target: $7
Current: $1.03
Upside: n/a
May 9, 2019
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: n/a
Apr 3, 2019
Reiterated: Buy
Price Target: $8
Current: $3.20
Upside: n/a